CIK 0001652130 · Large accelerated filer
Intellia Therapeutics, Inc.
Sign in to watch- Ticker
- NTLA
- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 364785571
- Phone
- 857-285-6200
- Business address
- 400 TECHNOLOGY SQUARE, SUITE 100, CAMBRIDGE, MA
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Open-market sale Director sold 501,945 shares at $60.29 ($30,262,716)
- S-8 Other Securities Offered to Employees in Benefit Plans
- 10-K Report Annual Report
- 8-K Event Results of operations
- SC 13G/A Stake Amended Statement of Ownership
- SC 13G/A Stake Amended Statement of Ownership
- SC 13G/A Stake Amended Statement of Ownership
- 4 Open-market sale EVP, General Counsel sold 11,489 shares at $75.00 ($861,675)
- 4 Open-market sale President and CEO sold 50,985 shares at an average $71.70 ($3,655,410)
- SC 13G/A Stake Amended Statement of Ownership
- 4 Open-market sale President and CEO sold 177,745 shares at an average $67.26 ($11,955,395)
- 4 Open-market sale EVP, General Counsel sold 54,659 shares at an average $63.99 ($3,497,902)
- SC 13G/A Stake Amended Statement of Ownership
- SC 13D/A Stake Beneficial Ownership Report
- 4 Option exercise Director acquired 20,000 shares (option exercise)
- 8-K Event Results of operations · Other events
- 4 Open-market sale President and CEO sold 6,239 shares at $55.86 ($348,511)
- 4 Open-market sale EVP, Chief Operating Officer sold 1,377 shares at $55.86 ($76,919)
Page 20 of 37 · 725 filings